News | July 28, 2023
Dr. Lal Path Labs Q1FY24 consolidated PAT up at Rs. 82.6 Cr
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Subscribe To Our Newsletter & Stay Updated
